Chris H. Takimoto - 23 May 2023 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Chief Medical Officer
Signature
/s/ Misbah Tahir, by power of attorney
Issuer symbol
IGMS
Transactions as of
23 May 2023
Net transactions value
-$4,232
Form type
4
Filing time
25 May 2023, 19:24:46 UTC
Previous filing
06 Apr 2023
Next filing
01 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Award $11,265 +962 +1.7% $11.71 56,001 15 May 2023 Direct F1
transaction IGMS Common Stock Sale $15,302 -1,244 -2.2% $12.30 54,757 23 May 2023 Direct F2, F3
transaction IGMS Common Stock Sale $195 -15 -0.03% $13.00 54,742 23 May 2023 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $12.00 to $12.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $13.00 to $13.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.